- Home
- LYEL vs ATLN Comparison
LYEL vs ATLN Comparison
Compare LYEL & ATLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- ATLN
- Stock Information
- Founded
- LYEL 2018
- ATLN N/A
- Country
- LYEL United States
- ATLN
- Employees
- LYEL N/A
- ATLN 7
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- ATLN
- Sector
- LYEL Health Care
- ATLN
- Exchange
- LYEL Nasdaq
- ATLN NYSE
- Market Cap
- LYEL 263.9M
- ATLN 248.2M
- IPO Year
- LYEL 2021
- ATLN N/A
- Fundamental
- Price
- LYEL $0.62
- ATLN $4.70
- Analyst Decision
- LYEL Sell
- ATLN
- Analyst Count
- LYEL 2
- ATLN 0
- Target Price
- LYEL $1.00
- ATLN N/A
- AVG Volume (30 Days)
- LYEL 1.5M
- ATLN N/A
- Earning Date
- LYEL 11-07-2024
- ATLN N/A
- Dividend Yield
- LYEL N/A
- ATLN N/A
- EPS Growth
- LYEL N/A
- ATLN N/A
- EPS
- LYEL N/A
- ATLN N/A
- Revenue
- LYEL $63,000.00
- ATLN N/A
- Revenue This Year
- LYEL N/A
- ATLN N/A
- Revenue Next Year
- LYEL N/A
- ATLN N/A
- P/E Ratio
- LYEL N/A
- ATLN N/A
- Revenue Growth
- LYEL N/A
- ATLN N/A
- 52 Week Low
- LYEL $0.58
- ATLN N/A
- 52 Week High
- LYEL $3.26
- ATLN N/A
- Technical
- Relative Strength Index (RSI)
- LYEL 27.76
- ATLN N/A
- Support Level
- LYEL $0.58
- ATLN N/A
- Resistance Level
- LYEL $0.95
- ATLN N/A
- Average True Range (ATR)
- LYEL 0.07
- ATLN 0.00
- MACD
- LYEL -0.02
- ATLN 0.00
- Stochastic Oscillator
- LYEL 6.48
- ATLN 0.00
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.